OBSOLETO. A síndrome mielodisplásica não classificada (SMD-U) é um subtipo de síndrome mielodisplásica (SMD) com características atípicas de significado clínico incerto.
Introdução
O que você precisa saber de cara
OBSOLETO. A síndrome mielodisplásica não classificada (SMD-U) é um subtipo de síndrome mielodisplásica (SMD) com características atípicas de significado clínico incerto.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 4 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 10 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Nenhum gene associado encontrado
Os dados genéticos desta condição ainda estão sendo catalogados.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Síndrome mielodisplásica, não classificada
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Pesquisa e ensaios clínicos
0 ensaios clínicos encontrados.
Publicações mais relevantes
JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.
Hypoxia-inducible factors (HIFs) are master transcriptional regulators, central to cellular survival in hypoxia and frequently activated within malignancy. Whilst malignant context directs the role of HIFs within oncogenesis, these mechanisms are not well characterised. Applying the JAK2V617F myeloproliferative neoplasms (MPNs) oncogene-driver model, in which HIF-1α is stabilised in normoxia (20% O2), we sought to determine whether the modality of HIF-1 activation directs its function. Through direct analysis of hypoxia-activated vs. JAK2V617F-activated HIF-1 at the chromatin, we define a JAK2V617F-HIF-1 regulon that diverges from canonical HIF/hypoxia targets. In a cohort of 172 JAK2V617F-MPN patients, we observe significant association of the JAK2V617F-HIF-1 regulon, but not canonical HIF-1 gene signatures, with disease severity, progression, and patient survival. We further define a subset gene signature (HIF1-MPN-BP) significantly associated with spontaneous transformation to blast phase MPNs. Finally, we identify that JAK2V617F-induced HIF-1α stabilisation is mediated via PIM1 kinase. Our findings demonstrate that HIF-1 activation by the JAK2V617F-PIM1 axis significantly alters HIF-1 transcription function, desensitising HIF-1 activity to cellular oxygen levels, and restricting the HIF-1 regulon to a set of disease-associated target genes within JAK2V617F-MPNs. These findings restore the potential for specific therapeutic targeting of HIF-1 by delineating malignant activation from the physiological hypoxic response.
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.
"Nonclassical" myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. Unlike classical MPNs, there is no standardized management approach for these conditions, particularly concerning the indications for and management of allogeneic hematopoietic cell transplantation. To address this gap, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee and the Chronic Malignancies Working Party (CMWP) have collaborated to develop shared guidelines aimed at optimizing the selection and management of patients with these rare forms of neoplasms. A comprehensive review of the literature from the publication of the revised fourth edition of the (2016) World Health Organization classification onward was conducted. A multidisciplinary group of experts in the field convened to produce this document, which was developed through multiple rounds of draft circulation. Key recommendations include the early identification of potential transplant candidates, particularly in cases of chronic neutrophilic leukemia, chronic eosinophilic leukemia (CEL)/CEL, not otherwise specified (CEL-NOS), myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions with FGFR1, JAK2, ABL1, and FLT3 rearrangements, MDS/MPN with neutrophilia/atypical chronic myeloid leukemia, and MDS/MPN, NOS. For patients with MPN, NOS/MPN unclassifiable, standard recommendations for myelofibrosis should be applied. Similarly, in MDS/MPN with thrombocytosis, transplantation is recommended on the basis of established MDS guidelines. Given the current lack of robust evidence, this document will serve as a valuable resource to guide future research activities, providing a framework for addressing critical unanswered questions and advancing the field.
Complex Interplay Between Sweet Syndrome and Therapy-Related Myelodysplastic Syndrome After B-Cell Lymphoma Treatment: A Case Report.
BACKGROUND Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is an inflammatory skin condition often associated with hematologic malignancies such as myelodysplastic syndrome (MDS). Therapy-related MDS (tMDS) is a well-recognized subtype of myelodysplastic syndrome that arises due to exposure to chemotherapy or radiation therapy. Reports on SS in the context of tMDS are limited, with unclear clinical features. CASE REPORT An 86-year-old woman with low-grade B-cell lymphoma, unclassifiable, achieved complete remission following bendamustine-rituximab therapy. She later developed cytomegalovirus viremia, persistent fever, and painful erythematous nodules. Histopathological examination of a skin biopsy confirmed SS. Corticosteroids and colchicine were initiated, leading to resolution of cutaneous symptoms. Despite clinical improvement, she developed progressive pancytopenia. Bone marrow evaluation revealed granulocytic dysplasia, including hypogranulation and pseudo-Pelger-Huët anomalies, with 1.5% ring sideroblasts and 3.2% blasts, consistent with MDS. Azacitidine was administered but proved ineffective in restoring hematopoiesis. The patient died due to an invasive Aspergillus brain abscess. Autopsy findings confirmed the absence of lymphoma recurrence. A literature review identified only 4 previously published cases of SS in tMDS, all of which occurred after the diagnosis of tMDS. CONCLUSIONS This case is notable in that SS preceded the diagnosis of MDS, contrasting with previous reports. Although a direct causal relationship cannot be established, this case underscores the diagnostic complexity of cutaneous and hematologic findings following chemotherapy. Furthermore, the absence of consensus on corticosteroid dosing and duration in immunocompromised hosts highlights the need to carefully balance therapeutic benefits against infection risk in SS associated with hematologic malignancies.
Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review.
Myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1) are rare, heterogenous, aggressive hematologic malignancies with FGFR1 rearrangements at the 8p11 locus. Pemigatinib, a potent selective inhibitor of FGFR1-3, is approved for relapsed/refractory MLN-FGFR1. This retrospective chart review included US adults with myeloproliferative neoplasm, unclassifiable (MPN-U), myelodysplastic syndrome (MDS)/MPN, post-MPN acute myelogenous leukemia, precursor T- or B-cell acute lymphoblastic leukemia/lymphoma, or mixed-phenotype acute leukemia with bone marrow biopsy and standard cytogenetic and/or molecular results. Probable cases of MLN-FGFR1 were identified and confirmed with cytogenetic or molecular testing results. Patient characteristics, diagnostic testing methods, treatments, and outcomes were abstracted. Of 560 submitted cases, 51 (9.1%) were probable MLN-FGFR1, 33 (5.9%) of which were subsequently confirmed. Among patients with confirmed MLN-FGFR1, 8p11 translocation or FGFR1 rearrangements were detected with standard cytogenetics in 72.7%, break-apart fluorescence in situ hybridization in 66.7%, next-generation sequencing in 21.2%, and real-time polymerase chain reaction in 6.1%. All but 1 patient initiated treatment; 3 patients underwent allogenic stem-cell transplant. This study highlights the importance of cytogenetic and molecular evaluations in patients with chronic/blast phase hematologic malignancies to diagnose MLN-FGFR1. This is particularly important following US approval of pemigatinib for this hematologic malignancy.
Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
The accurate diagnosis and classification of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are challenging due to the overlapping pathological and molecular features of myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN). We investigated the genomic landscape in different MDS/MPN subtypes, including chronic myelomonocytic leukemia (CMML; n = 97), atypical chronic myeloid leukemia (aCML; n = 8), MDS/MPN-unclassified (MDS/MPN-U; n = 44), and MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T; n = 12). Our study indicated that MDS/MPN is characterized by mutations commonly identified in myeloid neoplasms, with TET2 (52%) being the most frequently mutated gene, followed by ASXL1 (38.7%), SRSF2 (34.7%), and JAK2 (19.7%), among others. However, the distribution of recurrent mutations differs across the MDS/MPN subtypes. We confirmed that specific gene combinations correlate with specific MDS/MPN subtypes (e.g., TET2/SRSF2 in CMML, ASXL1/SETBP1 in aCML, and SF3B1/JAK2 in MDS/MPN-RS-T), with MDS/MPN-U being the most heterogeneous. Furthermore, we found that older age (≥65 years) and mutations in RUNX1 and TP53 were associated with poorer clinical outcomes in CMML (p < 0.05) by multivariate analysis. In MDS/MPN-U, CBL mutations (p < 0.05) were the sole negative prognostic factors identified in our study by multivariate analysis (p < 0.05). Overall, our study provides genetic insights into various MDS/MPN subtypes, which may aid in diagnosis and clinical decision-making for patients with MDS/MPN.
Publicações recentes
Complex Interplay Between Sweet Syndrome and Therapy-Related Myelodysplastic Syndrome After B-Cell Lymphoma Treatment: A Case Report.
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.
Clinical Characteristics and Diagnosis of Nonaccelerating MDS/MPN-U Patient with 5q- Karyotype.
Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study.
📚 EuropePMC1 artigos no totalmostrando 81
JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.
LeukemiaComplex Interplay Between Sweet Syndrome and Therapy-Related Myelodysplastic Syndrome After B-Cell Lymphoma Treatment: A Case Report.
The American journal of case reportsIdentification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review.
Acta haematologicaRole of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.
BloodAcute myeloid leukemia developed through myeloproliferative features during immunosuppressive therapy for juvenile idiopathic arthritis.
The journal of medical investigation : JMIClinical Characteristics and Diagnosis of Nonaccelerating MDS/MPN-U Patient with 5q- Karyotype.
Clinical laboratoryGenomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
International journal of molecular sciencesPrognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study.
Internal medicine (Tokyo, Japan)Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report.
BMC endocrine disordersA case of Behçet's-like disease associated with trisomy 8-positive myelodysplastic syndrome carrying MEFV E148Q variant presented with periodic fever.
Modern rheumatology case reportsA treatment-refractory aggressive MDS-MLD with multiple highly complex chromosome 5 intrachromosomal rearrangements: a case report.
Molecular cytogeneticsAllogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Bone marrow transplantation[Perforated upper gastrointestinal ulcers potentially attributable to mycophenolate mofetil after allogeneic hematopoietic stem cell transplantation].
[Rinsho ketsueki] The Japanese journal of clinical hematologyThe International Consensus Classification of myelodysplastic syndromes and related entities.
Virchows Archiv : an international journal of pathology[Haploidentical hematopoietic stem cell transplantation for graft failure in myelodysplastic syndrome/myeloproliferative neoplasm-unclassifiable complicated with Stenotrophomonas maltophilia bacteremia].
[Rinsho ketsueki] The Japanese journal of clinical hematologyExamining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.
EJHaemAutomated analysers underestimate atypical basophil count in myeloid neoplasms.
International journal of laboratory hematologyClinical Application for Diagnosis of Myelodysplatic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis.
Clinical laboratoryMDS/MPN-Unclassifiable with t(X;17)(q28;q21) and KANSL1-MTCP1/CMC4 Fusion Gene.
Cytogenetic and genome researchHybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Frontiers in oncologyMyelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncReal-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study.
MedicineA homozygous nonsense mutation early in exon 5 of BRCA2 is associated with very severe Fanconi anemia.
European journal of medical geneticsDevelopment of a myelodysplastic/myeloproliferative neoplasm-unclassifiable in a patient with acute myeloid leukemia: a case report and literature review.
The Journal of international medical researchAdult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS.
The Journal of allergy and clinical immunologyCo-occurrence of unclassified myeloproliferative neoplasm and giant cell arteritis in a patient treated with allogeneic hematopoietic stem cell transplantation: a case report and literature review.
Central-European journal of immunologyFavorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation.
SAGE open medical case reportsAre We Undercounting MDS? An Analysis of Incidence Patterns of Myelodysplastic Syndromes in SEER 21 Regions: 2001-2016.
Journal of registry managementJournal of Registry Management Continuing Education Quiz-WINTER 2021: Are We Undercounting MDS? An Analysis of Incidence Patterns of Myelodysplastic Syndromes in Seer 21 Regions: 2001-2016.
Journal of registry managementGenomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Hematology. American Society of Hematology. Education ProgramMyelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Hematology. American Society of Hematology. Education ProgramSpectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
Hematology/oncology and stem cell therapyComparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
Frontiers in oncologyRuxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS.
OncoTargets and therapyOligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
Blood advancesMolecular genetics of MDS/MPN overlap syndromes.
Best practice & research. Clinical haematologyViral metagenomics reveals diverse anelloviruses in bone marrow specimens from hematologic patients.
Journal of clinical virology : the official publication of the Pan American Society for Clinical VirologySalvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody.
Blood cell therapyMolecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
BloodMyelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Best practice & research. Clinical haematologyOutcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationA case of myelodysplastic syndrome with t(10;18)(q26;q21).
Journal of laboratory physiciansIron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis.
Clinical and experimental medicineGenetic alterations in 47 patients with a novel myelodysplastic syndrome diagnosis at a single center.
Oncology lettersClinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience.
Leukemia & lymphomaClinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.
LeukemiaOutcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013.
Mayo Clinic proceedingsGenomic landscape of neutrophilic leukemias of ambiguous diagnosis.
BloodDiagnostic Value of Flow Cytometry Standardized Using the European LeukemiaNet for Myelodysplastic Syndrome.
Acta haematologicaA case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation.
International journal of hematologyt(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression.
The Journal of molecular diagnostics : JMDChallenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).
Clinical lymphoma, myeloma & leukemiaMethylation level of Rap1GAP and the clinical significance in MDS.
Oncology lettersDyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
HaematologicaInflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.
European journal of haematologyAutoimmune manifestations associated with myelodysplastic syndromes.
Annals of hematologyLeukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies.
The Lancet. HaematologyAtypical chronic myeloid leukaemia: A case of an orphan disease-A multicenter report by the Polish Adult Leukemia Group.
Hematological oncology[Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Leukemia researchMyelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.
American journal of clinical pathologyMDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands.
Cancer epidemiologyOligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncSuspected myelodysplastic/myeloproliferative neoplasm in a feline leukemia virus-negative cat.
Veterinary clinical pathologyClinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Cancer biology & medicineAllogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Leukemia & lymphomaAn Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
Current hematologic malignancy reportsContext Matters: Distinct Disease Outcomes as a Result of Crebbp Hemizygosity in Different Mouse Bone Marrow Compartments.
PloS one[Identification of human erythroid lineage-committed progenitors].
[Rinsho ketsueki] The Japanese journal of clinical hematologyGenomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.
Genes, chromosomes & cancerSpectrum of the WHO Classification De Novo Myelodysplastic Syndrome: Experience from Southern Pakistan.
Asian Pacific journal of cancer prevention : APJCPMyelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable; rare cause of granulocytic sarcoma: A diagnostic dilemma.
Indian journal of pathology & microbiologyImpact of centralized evaluation of bone marrow histology in systemic mastocytosis.
European journal of clinical investigation[Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience].
Vnitrni lekarstviClinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.
American journal of clinical pathologySystemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.
Rheumatology (Oxford, England)[Current problems in the diagnosis of Philadelphia-negative myeloproliferative neoplasms in Japan].
[Rinsho ketsueki] The Japanese journal of clinical hematologyProspective isolation of human erythroid lineage-committed progenitors.
Proceedings of the National Academy of Sciences of the United States of AmericaImproving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes.
Journal of medical genetics[Analysis of the karyotype abnormalities and its prognostic in 298 patients with myelodysplastic syndrome].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFlow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Cytometry. Part B, Clinical cytometryAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Síndrome mielodisplásica, não classificada.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Síndrome mielodisplásica, não classificada
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.
- Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.
- Complex Interplay Between Sweet Syndrome and Therapy-Related Myelodysplastic Syndrome After B-Cell Lymphoma Treatment: A Case Report.
- Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review.
- Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
- Clinical Characteristics and Diagnosis of Nonaccelerating MDS/MPN-U Patient with 5q- Karyotype.
- Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:98827(Orphanet)
- MONDO:0020315(MONDO)
- Síndrome Mielodisplásica de Baixo Risco(PCDT · Ministério da Saúde)
- Busca completa no PubMed(PubMed)
- Q55789296(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
